By Carly Helfand
After an inspection from March 31 to April 9 of this year, the FDA didn’t much like what it saw at GlaxoSmithKline’s Ste-Foy plant in Quebec, home of the company’s FluLaval influenza vaccines. Now, the agency has issued a warning, pointing its finger at the British drugmaker for not doing its part to avoid contamination.
In a warning letter dated June 12 and posted to the FDA’s website Tuesday, the regulator highlighted ongoing bacteria problems that have resulted in GSK tossing more than 20 per cent of the lots it has produced this year alone. Continue reading